Altered number and distribution of cortical interneurons in Arid1b +/− mice. Arid1b-knockout mice were generated using embryonic stem cells that contain a 'knockout-first' design 13 of the targeted Arid1b allele harboring loxP sites flanking exon 5 ( Supplementary  Fig. 1 ). We first examined the lamination patterns of excitatory pyramidal neurons in postnatal day (P) 28 and P91 wild-type control (Arid1b +/+ ) and Arid1b +/− brains. Arid1b +/− cortices showed grossly normal CUX1 and TBR1 layering patterns, comparable to control cortices ( Supplementary Fig. 2 and Supplementary Table 1 ). Furthermore, we observed no substantial changes in the densities of CUX1 + , TBR1 + , or NeuN + neurons, nor in Olig2 + oligodendrocytes or GFAP + astrocytes in Arid1b +/− cortices ( Supplementary Fig. 2 ).
A utism spectrum disorder (ASD) impairs the ability of individuals to communicate and interact with others. Approximately 75% of individuals with ASD also have intellectual disability, which is characterized by significant limitations in cognitive functions and adaptive behaviors 1 . While ASD and intellectual disability are currently defined using behavioral criteria, little is known about the neuropathogenesis of these conditions. There are no pharmacological and/or genetic treatments to prevent ASD or intellectual disability, and current treatment options focus on behavioral management and educational and physical therapies. Development of therapeutic tools requires identification and targeting of causative factors.
Recent genetic studies have reported that haploinsufficiency of ARID1B causes ASD and nonsyndromic and syndromic intellectual disability including Coffin-Siris syndrome [2] [3] [4] . However, the neurobiological function of ARID1B during brain development is unknown. ARID1B is a component of the human Brg1/ Brm-associated factor (BAF) chromatin remodeling complex and controls gene expression by facilitating DNA access for transcription factors 5 . The ARID1B protein binds to DNA sequences via its AT-rich DNA-binding domain. Chromatin remodeling, as an epigenetic mechanism, is critically linked to ASD and intellectual disability 6 .
GABAergic interneurons play an important role in neural circuitry and in emotional and cognitive behaviors 7 . The balance of excitatory and inhibitory neurotransmission is essential for controlling memory and emotional behaviors and is disrupted in ASD and intellectual disability 8, 9 . Reduction of inhibitory signaling is particularly involved in ASD-like behaviors in humans and in mouse models of ASD 10, 11 . Proper positioning and differentiation of interneurons during brain development are important for establishing anatomical and functional circuitry necessary for normal cognition 12 .
To investigate the neurobiological role of Arid1b, we generated Arid1b-knockout mice. Arid1b-heterozygous mice in particular could be an excellent model for disorders related to ARID1B haploinsufficiency. We found that Arid1b haploinsufficiency leads to an excitation-inhibition imbalance by reducing the number of GABAergic interneurons in the cerebral cortex. Furthermore, we showed that treatment with a GABA A -receptor positive allosteric modulator rescues ASD-like behavior and cognitive dysfunction in Arid1b-heterozygous mice, suggesting an association between lower numbers of GABAergic interneurons and behavioral outcomes. Our findings suggest a pathogenic mechanism for ASD and intellectual disability.
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the Dlx5/6-Cre-IRES-EGFP 14 or Nkx2.1-Cre 15 mouse line. The densities of GABA + and parvalbumin + neurons were decreased in Arid1b loxP/+ ;Dlx5/6-Cre-IRES-EGFP and Arid1b loxP/+ ;Nkx2.1-Cre cortices compared with Arid1b +/+ ;Dlx5/6-Cre-IRES-EGFP and Arid1b +/+ ;Nkx2.1-Cre controls ( Supplementary Fig. 5a-g) . Conditional deletion of Arid1b did not lead to substantial changes in GABA + or parvalbumin + cells were counted in layers I-VI of the cortex at P91. Histograms show the total number of GABA + or parvalbumin + cells throughout cortical layers (left; GABA: t 18 = 4.372, ***P = 0.0004; parvalbumin: t 18 = 5.927, ***P < 0.0001) and in each layer (right; GABA layer IV: t 18 = 3.769, **P = 0.0014; GABA layer V: t 18 = 4.794, ***P = 0.0001; GABA layer VI: t 18 = 3.024, **P = 0.0073; parvalbumin layer IV: t 18 = 4.515, ***P = 0.0003; parvalbumin layer V: t 18 = 4.386, ***P = 0.0004; parvalbumin layer VI: t 18 = 2.496, *P = 0.0225); n = 10 mice each for Arid1b +/+ (8 males, 2 females) and Arid1b +/− (7 males, 3 females); two-tailed Student's t test). e-h, Interneurons expressing EGFP were assessed in E12.5 (e) and E16.5 (g) cortices from Arid1b +/+ ;Dlx5/6-Cre-IRES-EGFP and Arid1b +/− ;Dlx5/6-Cre-IRES-EGFP mice. Scale bar, 400 μ m. (f,h) Quantified numbers of cortical interneurons shown in e (region 1: t 8 = 2.849, *P = 0.0215; region 2: t 8 = 3.664, **P = 0.0064; region 3: t 8 = 2.495, *P = 0.0372) and g (region 1: t 8 = 3.112, *P = 0.0144; region 2: t 8 = 2.545, *P = 0.0344; region 3: t 8 = 3.044, *P = 0.016). The cortex was divided into three equally defined regions along the lateral cortex, as indicated by dashed boxes and numbers; n = 5 mice for each age and group; two-tailed Student's t test. Data shown as mean ± s.e.m.
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Nature NeuroscieNce body weight in mutant mice ( Supplementary Fig. 5h ). The reduced cortical interneurons in postnatal Arid1b +/− mice led us to examine whether the abnormalities observed in mutants began during embryonic development. The number of EGFP + interneurons was significantly reduced in Arid1b +/− ;Dlx5/6-Cre-IRES-EGFP cortices at embryonic day (E) 12.5, E14.5, E16.5, and E18.5 compared with controls ( Fig. 1e-h and Supplementary Fig. 6 ). Taken together, these results show that Arid1b haploinsufficiency leads to a substantial reduction in cortical interneurons.
Development of cortical interneurons in Arid1b +/− mice.
Interneuron migration plays an important role in determining the quantity and positioning of cortical interneurons. Using time-lapse imaging of EGFP + interneurons on cortical slices from E13.5 control (Arid1b +/+ ;Dlx5/6-Cre-IRES-EGFP) and Arid1b +/− ;Dlx5/6-Cre-IRES-EGFP mice, we found no substantial differences in migration speeds in Arid1b +/− interneurons compared with controls ( Fig. 2a-c) . We then examined the proliferation of Arid1b +/− ventral progenitors in the medial ganglionic eminence (MGE), which is the primary source of cortical interneurons in the developing brain. The number of proliferating cells positive to phosphorylated histone-H3 or BrdU was decreased in Arid1b +/− MGEs compared with controls ( Fig. 2d,e ). Next, we assessed apoptotic cells in control and Arid1b +/− MGEs and lateral ganglionic eminences (LGEs) by cleaved caspase-3 staining and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. The numbers of cleaved caspase-3 + and TUNEL + cells were increased in Arid1b +/− MGEs and
LGEs ( Fig. 2f,g) . The cells whose rate of apoptosis increased in the MGE were progenitors, as they were double-positive to phosphorylated-histone H3 and cleaved caspase-3 ( Fig. 2h ). To further confirm our observations, we assessed cell death in cultured MGE progenitors. The number of proliferating progenitors labeled with BrdU was decreased in Arid1b +/− cultures compared with controls, while the numbers of cleaved caspase-3 + or TUNEL + cells were increased ( Fig. 2i-l) . These results suggest that Arid1b haploinsufficiency reduces the number of cortical interneurons by inhibiting proliferation and promoting apoptosis of ganglionic eminence progenitors during brain development. We examined expression of the components in Wnt-β -catenin signaling, which plays an important role in ventral progenitor proliferation and development. The protein levels of β -catenin and its target, cyclin D1, were decreased in Arid1b-knockout ventral telencephalons in a gene-dose-dependent manner, while the level of phospho-β -catenin was increased ( Supplementary Fig. 7a ,b). The transcript levels of Ctnnb1 and its target genes as well as Wnt family genes were mostly downregulated in Arid1b-knockout samples ( Supplementary Fig. 7c,d ).
We investigated neurite morphology of Arid1b-heterozygous interneurons by tracing EGFP + cells in P91 Arid1b +/− ;Dlx5/6-Cre-IRES-EGFP mice. The length and number of Arid1b +/− interneuron neurites were decreased in Arid1b +/− ;Dlx5/6-Cre-IRES-EGFP mice compared with Arid1b +/+ ;Dlx5/6-Cre-IRES-EGFP mice ( Supplementary Fig. 8 ).
Synaptic structure and function in Arid1b +/− mice. The altered number and morphology of interneurons suggest that the Arid1b +/− cortex may have abnormal neuronal connectivity. Indeed, the numbers of inhibitory synaptic puncta positive to vesicular inhibitory amino acid transporter (VIAAT; also called Slc32a1) and glutamic acid decarboxylase 2 (GAD2) were decreased in Arid1b +/− cortices compared with control numbers (Fig. 3a,b ). However, we found no change in the number of excitatory synaptic puncta positive for vesicular glutamate transporter 1 (VGluT1; also called Slc17a7) in Arid1b +/− cortices. Also, we observed no changes in the number of excitatory synapses assessed by colocalized puncta of the postsynaptic marker disks large homolog 4 (PSD95) and presynaptic marker VGluT1 in P91 Arid1b +/− cortices ( Supplementary Fig. 9 ). We measured the ratio of VGluT1 + to VIAAT + synapses in cortical layers II/III. Arid1b +/− cortices exhibited a higher ratio of excitatory to inhibitory synapses than controls ( Fig. 3c ), suggesting excitatory-inhibitory (E/I) imbalance. Additionally, using real-time PCR, we found that the levels of Gad1 and Gad2 mRNAs were downregulated in Arid1b +/− cortices ( Fig. 3d and Supplementary Fig. 7e ). The mRNA levels of inhibitory postsynaptic markers Gphn and Arhgef9 were decreased in Arid1b +/− cortices, while the levels of excitatory markers Slc17a7 and Dlg4 were not changed in Arid1b +/− cortices compared with control levels. However, Arid1b −/− cortices showed reduced levels of Slc17a7 and Dlg4 compared with wild-type and Arid1b +/− samples ( Supplementary Fig. 7e ). GABA receptor levels were not changed in Arid1b +/− samples but were decreased in Arid1b −/− samples ( Fig. 3d and Supplementary Fig. 7e ). GAD1 was also decreased in Arid1b +/− cortices (Fig. 3e ,f).
To determine whether Arid1b haploinsufficiency affects excitatory and inhibitory neurotransmission, we performed whole-cell recordings on pyramidal neurons in cortical slices. No changes were found in the frequency, interevent interval, or amplitude of miniature excitatory postsynaptic currents (mEPSC) between control and Arid1b +/− neurons ( Fig. 4a and Supplementary Fig. 10a ). In contrast, the frequency of miniature inhibitory postsynaptic currents (mIPSC) was decreased in Arid1b +/− cortical neurons compared with controls ( Fig. 4b and Supplementary Fig. 10b ). The cumulative-fraction curves revealed increased interevent intervals in Arid1b +/− cortical neurons. We further examined the morphology of inhibitory synapses in Arid1b +/− mice. Arid1b +/− cortices at P91 showed an increase in the cleft width of symmetric synapses compared with controls, whereas they had a decreased length of postsynaptic density (Fig. 4c,d ). Together, our data show that Arid1b haploinsufficiency results in E/I imbalance via abnormal formation and transmission of inhibitory synapses.
Arid1b haploinsufficiency disrupts epigenetic programing. We assessed histone H3 acetylation and methylation, which are essential for transcription regulation, in Arid1b +/− brains. We found that the levels of transcriptional activators histone H3 acetylation at lysine 9 (H3K9ac) and histone H3 trimethylation at lysine 4 (H3K4me3) were decreased in Arid1b +/− cortices compared with control levels, while the level of the transcriptional repressor histone H3 trimethylation at lysine 27 (H3K27me3) was increased ( Fig. 5a,b and Supplementary Fig. 7a,b ). Arid1b −/− cortices contained H3K9ac and H3K4me3 levels similar to those in Arid1b +/− samples but increased H3K27me3 ( Supplementary Fig. 7a,b ). The levels of all histone subunits, such as H1, H2A, H3, and H4, showed no changes between Arid1b +/− and control samples ( Fig. 5a,c) . These results suggested that Arid1b haploinsufficiency might suppress the activity of histone acetyltransferases (HATs) or enhance the activity of histone deacetylases (HDACs) in the brain. However, HAT and HDAC assays showed no differences in the activity of the histone modifiers between control and Arid1b +/− cortices ( Fig. 5d ). H3K9 acetylation can be regulated by the amounts of HATs or HDACs, as well as by their levels of activity. Compared with controls, Arid1b +/− cortices showed no changes in mRNA levels of several HATs and HDACs including Crebbp (Cbp), Ep300, Kat2b (Pcaf), Kat5, Hdac1, Hdac2, Hdac3, and Hdac4 (Fig. 5e ). We further assessed the levels of histone deacetylase 4 localized in the nucleus and cytosol because nuclear accumulation of the protein is associated with neuronal development. Again, there was no change in nuclear accumulation of this histone deacetylase between Arid1b +/− and control cortices ( Fig. 5f ). Notably, the protein level of acetyl-CREB-binding protein (CBP), which enhances HAT function, was decreased in Arid1b +/− cortices, while the levels of CBP and PCAF were not altered ( Fig. 5g,h and Supplementary Fig. 7a,b) . However, the level of PCAF in Arid1b −/− cortices was decreased compared with control and Arid1b +/− sample levels ( Supplementary Fig. 7a,b ). Next, we examined the physical LGEs by immunostaining using a cleaved caspase-3 antibody or TUNEL assays. Scale bars, 100 μ m. g, Quantification of f. Mutant GEs had more dying cells (n = 6 mice for each group; two-tailed Student's t test; cleaved caspase-3 + : MGE, t 10 = 6.246, ***P < 0.0001; LGE, t 10 = 9.561, ***P < 0.0001; TUNEL: t 10 = 7.296, ***P < 0.0001). h, The number of cells double-positive for cleaved caspase-3 and p-histone-H3 was increased in the Arid1b +/− MGE at E14.5 (t 18 = 4.667, ***P = 0.0002; n = 10 mice for each genotype; two-tailed Student's t test). i, MGE primary cells were cultured from E12.5 Arid1b +/+ and Arid1b +/− mice for 2 d. The cells were then incubated with 10 μ M BrdU for 24 h, fixed and immunostained with cleaved caspase-3 and BrdU antibodies. Scale bar, 40 μ m. j, Quantification of i; n = 6 cell culture replicates using 6 mice for each condition (cell counts: 1,023 cells for Arid1b +/+ and 646 cells for Arid1b +/− ; two-tailed Student's t test; cleaved caspase-3: t 10 = 2.419, *P = 0.0361; BrdU: t 10 = 3.520, **P = 0.0055). k, After 2 d of MGE culture, the TUNEL assay was performed. Scale bar, 40 μ m. l, Quantification of TUNEL + cells. Apoptosis was increased in Arid1b-mutant cells (t 10 = 6.982, ***P = 0.0001; n = 6 cell culture replicates using 6 mice for each condition; cell counts: 598 cells for Arid1b +/+ and 605 cells for Arid1b +/− ; two-tailed Student's t test). Data shown are mean ± s.e.m
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Nature NeuroscieNce association of H3K9ac and HATs. ARID1B could potentially mediate the interaction between HATs and histone H3. Indeed, using co-immunoprecipitation (co-IP) we found decreased levels of CBP and PCAF bound to H3K9ac in Arid1b +/− cortices compared with controls ( Fig. 5i,j) . We verified the reduced binding of the HATs and histone H3 using another method, proximity-dependent biotin identification (BioID2) 16 . As in the co-IP results, the levels of CBP and PCAF bound to histone H3 were decreased in Arid1b +/− samples ( Fig. 5k,l) . These data suggest that ARID1B may function as a bridge between histone H3 and HATs.
Arid1b haploinsufficiency led to decreased levels of Pvalb and Ntrk2 transcripts ( Fig. 5m ). Thus, we investigated whether ARID1B regulates histone H3 acetylation in the Pvalb promoter using a chromatin-immunoprecipitation quantitative PCR (ChIP-qPCR) assay. The upstream regions adjacent to the transcription start site of the first exon were analyzed ( Fig. 5n ). We found that ARID1B bound to the Pvalb promoter around the transcription start site in control cortices ( Fig. 5o,p) . ARID1B binding to Pvalb promoter regions 1 and 2 was decreased in Arid1b +/− cortices, whereas Pvalb promoter region 3 binding was not changed. To verify that ARID1B binding at the Pvalb promoter causes expression changes via epigenetic mechanisms, we performed other sets of ChIP-qPCR experiments. First, we included two negative controls. We examined whether ARID1B binds to a distal intergenic or an intron region of the Pvalb gene. We found no binding of ARID1B to these regions ( Supplementary  Fig. 11a,b ). Second, we performed ChIP-qPCR to investigate two promoter regions of excitatory-neuron-relevant genes Slc17a7 and Dlg4. The mRNA levels of these genes were not changed in Arid1b +/− cortices compared with control levels ( Fig. 3d and Supplementary  Fig. 7e ). We found that ARID1B bound to the Slc17a7 and Dlg4 promoters around transcription start sites, but the levels of ARID1B binding were not different between control and Arid1b +/− cortices ( Supplementary Fig. 11c,d ). Finally, we performed two more sets of ChIP-qPCR assays, examining ARID1B binding to the promoters of inhibitory-neuron-relevant Gad1 and Slc32a1 genes. Expression of these genes was downregulated in Arid1b +/− cortices ( Fig. 3d and Supplementary Fig. 7e ). ARID1B was associated with Gad1 and Slc32a1 promoter regions in wild-type and Arid1b +/− cortical tissues ( Supplementary Fig. 11e ,f). The levels of ARID1B binding to the promoters were decreased in Arid1b +/− samples compared with controls. These results suggest an adverse effect of Arid1b haploinsufficiency on gene expression related to interneuron development.
Next, we examined the association of H3K9ac with the Pvalb promoter in Arid1b +/− cortices. H3K9ac bound to the Pvalb promoter regions, but the levels of H3K9ac in Pvalb promoter regions 1 and 2 were decreased in Arid1b +/− cortices, similarly to the ARID1B interaction pattern to the Pvalb promoter ( Fig. 5q ,r). To verify that the reduced H3K9ac signature and transcription were specific to the Pvalb gene in parvalbumin cells, we measured the level of H3K9ac binding to promoters of Syt2 and Ppargc1a, which are specifically expressed in parvalbumin interneurons but not in other types of interneurons or in excitatory neurons [17] [18] [19] . We found that Syt2 and Ppargc1a mRNA levels were not significantly altered in Arid1b +/− cortices compared with the control levels ( Supplementary  Fig. 12a ). The ChIP-qPCR assay showed that H3K9ac bound to Syt2 and Ppargc1a promoters in control and Arid1b +/− cortices ( Supplementary Fig. 12b -g). The levels of H3K9ac binding to the promoters were not changed in Arid1b +/− samples. These results suggest that, by controlling physical access of histone modifiers and subsequently creating favorable and relaxed chromatin environments, ARID1B may facilitate Pvalb gene transcription. Thus, we tested whether ARID1B haploinsufficiency interferes with the initiation of Pvalb gene transcription. We performed a ChIP-qPCR assay using an antibody to phosphorylated (Ser5)-carboxy-terminal domain (CTD) of RNA polymerase II. CTD is distinctly phosphorylated at the serine 5 residue only during transcription initiation.
The levels of phospho-CTD (Ser5) associated with the Pvalb promoter were decreased in Arid1b +/− cortices compared with control levels (Fig. 5s ,t), indicating that transcription initiation of the Pvalb gene was suppressed in Arid1b +/− cortices. Transcription initiation at the Ntrk2 gene was similarly suppressed in Arid1b +/− cortices ( Supplementary Fig. 11g -i). In contrast, the levels of phospho-CTD (Ser5) in the Syt2 promoter were not different between control and Arid1b +/− cortices ( Supplementary Fig. 12h ,i). Together, our data suggest that ARID1B regulates Pvalb gene expression by recruiting HATs to histone molecules on the target promoter and facilitating chromatin remodeling for transcription initiation control.
Abnormal cognitive and social behavior in Arid1b +/− mice. To address the functional relevancy of the morphological and biochemical changes in Arid1b +/− mice, we examined cognitive, social, and emotional behaviors that model clinical features of ASD and intellectual disability. We first performed the Morris water maze test. During the acquisition phase, the differences in escape latency time between the two genotypes continued in a consistent manner after 4 d of training ( Fig. 6a ), indicating that the capacity for spatial learning in Arid1b +/− mice is limited, rather than delayed. In the probe trial, Arid1b +/− mice crossed the platform location fewer times, whereas control and Arid1b +/− mice showed no differences in swimming distances and swimming speeds ( Fig. 6b,c) . In the T-maze test, Arid1b +/− mice exhibited impaired spatial reference memory ( Fig. 6d ). We also assessed recognition memory using a novel object recognition test. While control mice spent more time approaching and in proximity to the novel object, Arid1b +/− mice did not show any preference for exploring either familiar or novel objects ( Fig. 6e ). Arid1b-conditional-mutant mice (Arid1b loxP/+ ;Dlx5/6-Cre-IRES-EGFP) showed similar impairments in recognition memory ( Supplementary Fig. 13a ). Additionally, the rotarod test revealed motor learning defects in Arid1b +/− mice (Fig. 6f ). These results demonstrate that Arid1b +/− mice have impaired cognitive functioning in areas such as spatial and nonspatial learning and memory.
Next, we used the three-chamber social test to assess social interaction behavior. In the sociability test, control mice spent more time in the chamber containing an unfamiliar mouse than in the empty chamber, whereas Arid1b +/− and Arid1b loxP/+ ;DLX-Cre-IRES-EGFP mice showed no preference for either chamber ( Fig. 6g and Supplementary Fig. 13b ). In the social novelty test, control mice showed preference for the second unfamiliar mouse, whereas Arid1b +/− and Arid1b loxP/+ ;DLX-Cre-IRES-EGFP mice spent more time in the chamber containing the first, more familiar, mouse. Social interaction abnormalities in Arid1b +/− mice were confirmed in an open field apparatus. Arid1b +/− mice exhibited reduced time spent on general sniffing, anogenital sniffing, and following behavior ( Fig. 6h ). Notably, approximately 20% of Arid1b +/− mice demonstrated excessive grooming behavior, resulting in severe selfinjury, such as torn ears or hair loss on the face, neck, and shoulder regions (Fig. 6i,j) . Excessive grooming was also observed in Arid1b LoxP/+ ;Dlx5/6-Cre-IRES-EGFP and Arid1b LoxP/+ ;Nkx2.1-Cre mice ( Supplementary Fig. 13c ). These results show that Arid1b +/− mice exhibit impaired social interaction and repetitive behaviors, which are core features of ASD.
Individuals with ASD frequently experience heightened anxiety. Using the elevated plus maze test and the open field test, we found that Arid1b +/− and Arid1b loxP/+ ;DLX-Cre-IRES-EGFP mice showed increased anxiety (Fig. 6k,l and Supplementary Fig. 13d,e ). Arid1b mutant mice showed decreased moving distances in the open field test compared with wild-type mice ( Supplementary Fig. 14a,b ). We also performed forced swim tests and tail suspension tests to assess depression-related behavior. Arid1b +/− mice showed markedly increased immobilization behavior in both tests compared with control mice (Fig. 6m ). Together, our behavioral assessments of Arid1b +/− mice show that Arid1b haploinsufficiency diminishes Articles Nature NeuroscieNce intellectual functioning and social interaction and elevates anxietylike behavior.
Because Arid1b +/− mice showed a decreased number of GABAergic interneurons in the brain, we examined whether pharmacological modulation of GABA activity could rescue the abnormal behaviors observed in Arid1b +/− mice. We first performed novel-object recognition tests on control and Arid1b +/− mice after intraperitoneal injection of clonazepam, a positive allosteric modulator of the GABA A receptor. Treatment with clonazepam increased the amount of time Arid1b +/− mice spent investigating the novel object to that exhibited by wild-type mice (Fig. 7a ). In the three-chamber social test, clonazepam treatment did not induce changes in the measured sociability of either control or Arid1b +/− mice (Fig. 7b ). When a second stranger mouse was introduced for the social novelty assessment, however, clonazepam treatment of Arid1b +/− mice successfully rescued the impaired social novelty Arid1b +/+ and Arid1b +/− cortices were examined by immunostaining using antibodies to inhibitory presynaptic markers VIAAT and GAD2 and excitatory presynaptic marker VGluT1. Scale bar, 5 μ m. b, Quantification of a. Numbers of VIAAT + and GAD2 + synaptic puncta were decreased in Arid1b +/− mice at P91, while the number of excitatory presynaptic puncta was not different (VIAAT: t 18 = 4.823, ***P = 0.0001; n = 10 mice for Arid1b +/+ (8 males, 2 females) and Arid1b +/− (7 males, 3 females); GAD2: t 44 = 4.226, ***P = 0.0001; n = 23 mice for Arid1b +/+ (13 males, 10 females) and Arid1b +/− (14 males, 9 females); VGluT1: n = 15 mice for Arid1b +/+ (7 males, 8 females) and Arid1b +/− (7 males, 8 females); two-tailed Student's t test). c, Dot plot shows the ratio of VGluT1 + to VIAAT + puncta measured in a and b. Histogram shows the puncta ratio per 2,500 μ m 2 area in the cortex. There was an increase in this ratio in Arid1b +/− cortical samples (t 54 = 4.435, ***P < 0.0001; n = 28 mice for Arid1b +/+ (15 males, 13 females) and Arid1b +/− (14 males, 14 females); two-tailed Student's t test). d, mRNA levels of Gad1, Gad2, Gphn, Arhgef9, Slc17a7, Dlg4, Gabra1, Gabrb2, and Gabrg2 were assessed in P91 Arid1b +/+ and Arid1b +/− cortical tissues using real-time PCR (Gad1: t 18 = 2.709, *P = 0.0144; Gad2: t 18 = 2.960, **P = 0.0084; Gphn: t 18 = 3.865, **P = 0.0011; Arhgef9: t 18 = 2.506, *P = 0.0201; n = 10 independent experiments using 10 mice for each group; two-tailed Student's t test). e, Western blotting with an antibody to GAD1 was performed using cortical lysates from P91 Arid1b +/+ and Arid1b +/− mice. f, Quantification of e (n = 3 independent experiments using 6 mice for each group; t 4 = 3.424, *P = 0.0367). The intensity of protein and mRNA was normalized to the GAPDH level. Data were shown as relative changes versus Arid1b +/+ controls; statistical significance was determined by a two-tailed Student's t test. Data shown are mean ± s.e.m.
Articles Nature NeuroscieNce phenotype. Clonazepam also reversed the reduced time spent in the center and reduced moving distance displayed by Arid1b-mutant mice in the open field test (Fig. 7c,d and Supplementary Fig. 14c ). However, depression measures, using the forced swim test and the tail suspension test, showed no reversible effect of clonazepam in Arid1b +/− mice compared with controls ( Fig. 7e,f 
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in Arid1b +/− cortical slices was also reversed by clonazepam treatment ( Supplementary Fig. 14d ), but mIPSC amplitude was not changed in any condition. Full length western blots are presented in Supplementary Fig. 15 .
Discussion
Despite recent advances in genetic studies of ASD and intellectual disability, the underlying mechanisms for these neurological conditions remain poorly understood. In this study, we showed that haploinsufficiency of the chromatin remodeling complex gene Arid1b disrupts normal interneuron development and function in the mouse brain. This is an important finding because, while ARID1B haploinsufficiency is known to cause ASD and intellectual disability [2] [3] [4] 20 , the cellular and molecular basis for ARID1B-haploinsufficiency-related neurodevelopmental disorders has not been delineated.
Our results suggest that ARID1B haploinsufficiency disrupts normal histone modifications and histone modifier access to some genes related to interneuron development. Another significant impact of this study is the creation of an animal model for ARID1B haploinsufficiency. The behavioral phenotypes of this mouse recapitulate the deficits in cognitive and social functions observed in individuals with ASD or intellectual disability. This mouse model can be further used for anatomical and functional studies examining abnormal neurodevelopmental conditions.
We found that cortical GABAergic interneurons were decreased in Arid1b +/− and Arid1b-conditional-knockout mice, while interneuron migration routes and speeds remained normal. Thus, the 
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Nature NeuroscieNce depletion of interneurons in the cerebral cortex appears to be caused by defective proliferation and maintenance of interneuron progenitors in the MGE, the origin of as much as 60-80% of cortical interneurons 21 . This decrease in cortical interneurons in Arid1b +/− and Arid1b-conditional-knockout mice was largely specific to parvalbumin + neurons. The number of calretinin + interneurons, which are mainly derived from the caudal ganglionic eminence, was not altered in Arid1b +/− mice, suggesting that ARID1B haploinsufficiency may induce differential spatial sensitivity in progenitor regulation. Reduced inhibitory neurons may induce a compensatory increase in the number or level of inhibitory postsynaptic components in Arid1b mutant brains. However, the levels of postsynaptic inhibitory components Gphn and Arhgef9 were decreased in Arid1b +/− cortices compared with control samples. Thus, in addition to the decreased inhibitory inputs, reduced reception capacity appears to contribute to the disrupted inhibitory transmission in Arid1b +/− mice. Cortical excitatory neurons derived from radial progenitors showed grossly normal positioning, numbers, and neurite morphology in Arid1b +/− mice. Our previous work showed that Arid1b knockdown reduces dendritic arborization in cortical pyramidal neurons 22 . That study used shRNA to knock down Arid1b. One of the limitations in shRNA-mediated gene knockdown is the difficulty in controlling the quantity of gene knockdown. Knocking out more than half of Arid1b functionality could alter pyramidal neuron morphology. GABAergic interneurons play an important role as inhibitory neurons in neural circuitry by regulating pyramidal neuron activity. Alterations in parvalbumin interneuron numbers and Pvalb mRNA levels have been reported in the brains of humans with autism [23] [24] [25] [26] [27] [28] . Imbalanced E/I is associated with the brain composition of humans with autism and is generally caused by deficient GABAergic signaling, leading to broken circuit homeostasis 8, 29 . Pvalb-knockout mice also show core symptoms of ASD and exhibit E/I imbalance 30, 31 . Arid1b +/− mice showed a decrease in platform crossings (t 16 = 3.868, **P = 0.0014; two-tailed Student's t test). d, In the T-maze test, Arid1b +/− mice have a lower success rate of food retrieval compared with Arid1b +/+ mice (t 10 = 6.991, ***P < 0.0001; n = 6 mice (3 males, 3 females) for each genotype; two-tailed Student's t test). e, Results of the novel-object recognition test (t 15 = 4.749, ***P = 0.0003; n = 9 (5 males, 4 females) for Arid1b +/+ mice; N = 8 (5 males, 3 females) for Arid1b +/− mice; two-tailed Student's t test). f, In the rotarod test, the latency to fall during test phases was reduced in Arid1b +/− mice (4 d: t 34 = 2.359, *P = 0.0242; 6 d: t 34 = 2.198, *P = 0.0353; 13 d: t 34 = 2.141, *P = 0.0397; n = 6 mice (3 males, 3 females) for each genotype; two-tailed Student's t test). g, Three-chamber sociability test results for Arid1b +/+ and Arid1b +/− mice (t 20 = 6.313, ***P < 0.0001). In the social novelty test, Arid1b +/− mice spent less time with the novel mouse (stranger II) than with the familiar mouse (stranger I; Arid1b +/+ : t 20 = 4.874, ***P < 0.0001; Arid1b +/− : t 22 = 4.900, ***P < 0.0001; n = 11 male mice for Arid1b +/+ and 12 male mice for Arid1b +/− ; two-tailed Student's t test). h, Social interaction was performed using an open field apparatus. Left: Arid1b +/− mice showed decreased interaction compared with Arid1b +/+ mice (general sniffing: t 10 = 3.678, **P = 0.0043; anogenital sniffing: t 10 = 3.872, **P = 0.0031; following: t 10 = 0.867, **P = 0.0031). Right: quantification of total sniffing time (t 10 = 3.896, **P = 0.0033; n = 6 male mice for each genotype; two-tailed Student's t test). i, Excessive grooming led to severe facial, neck, and shoulder lesions in Arid1b +/− mice (red arrows). j, Arid1b +/− mice showed increased grooming time compared with Arid1b +/+ mice (t 18 = 13.64, ***P < 0.0001; n = 10 mice for Arid1b +/+ (6 males, 4 females) and Arid1b +/− (5 males, 5 females); two-tailed Student's t test). k, In the elevated plus maze test, Arid1b +/− mice spent less time in the open arms (t 23 = 3.251, **P = 0.0035; n = 13 mice (7 males, 6 females) for Arid1b +/+ and 12 mice (6 males, 6 females) for Arid1b +/− ; two-tailed Student's t test). l, Time spent in the center and the numbers of entries into the center were examined in the open field (time in center: t 34 = 7.189, ***P < 0.0001; center entries: t 34 = 4.713, ***P < 0.0001; n = 16 mice (9 males, 7 females) for Arid1b +/+ and 20 mice (11 males, 9 females) for Arid1b +/− ; two-tailed Student's t test). m, In both the forced swim test and the tail suspension test, the immobility time was increased in Arid1b +/− mice (forced swim test: t 23 = 9.169, ***P < 0.0001; tail suspension test: t 23 = 6.416, ***P < 0.0001; n = 12 mice (7 males, 5 females) for Arid1b +/+ and 13 mice (7 males, 6 females) for Arid1b +/− ; two-tailed Student's t test). Data shown are mean ± s.e.m.
Nature NeuroscieNce
Our mouse model of ASD consistently shows a selective reduction of parvalbumin + neurons as well as E/I imbalance in structural and functional synaptic connectivity. The decrease in GABAergic interneurons may cause imbalanced excitation and inhibition in Arid1b +/− brains, leading to abnormal behavior similar to ASD. Aberrant neural mechanisms during interneuron development, such as proliferation, placement, neurite outgrowth, and synapse formation, might induce behavioral phenotypes individually or cooperatively in Arid1b +/− mice. Specific aspects of interneuron development that play a key role in Arid1b-haploinsufficiency-driven behavior remain to be elucidated. Also, we do not exclude the possibility that some impacts in excitatory neurons caused by Arid1b deficiency could have contributed to abnormal behavior in Arid1b-mutant mice.
Our results demonstrate that the levels of histone acetylation and methylation were decreased in Arid1b +/− mice, suggesting a role of ARID1B in remodeling the chromatin complex by inducing the physical access of histone modifying enzymes, such as PCAF and CBP, to histone molecules. As a result, the target genes Either saline or 0.0625 mg/kg clonazepam was administered to control and Arid1b +/− mice intraperitoneally, followed by the object recognition test (Arid1b +/+ + saline: t 14 = 9.402, ***P < 0.0001; Arid1b +/+ + clonazepam: t 20 = 11.34, ***P < 0.0001; Arid1b +/-+ saline: t 12 = 0.667, P = 0.517; Arid1b +/− + clonazepam: t 22 = 8.345, ***P < 0.0001; n = 8 mice (5 males, 3 females) for saline-treated Arid1b +/+ , 10 mice (7 males, 3 females) for clonazepam-treated Arid1b +/+ , 7 mice (5 males, 2 females) for saline-treated Arid1b +/− , and 10 mice (6 males, 4 females) for clonazepam-treated Arid1b +/− ; two-tailed Student's t test). b, In the sociability test, clonazepam-treated Arid1b +/− mice had no preference for either chamber (Arid1b +/+ + saline: t 16 = 6.082, ***P < 0.0001; Arid1b +/+ + clonazepam: t 16 = 6.153, ***P < 0.0001). However, the social novelty test showed that social memory in Arid1b +/− mice was restored by clonazepam treatment (Arid1b +/+ + saline: t 16 = 6.767, ***P < 0.0001; Arid1b +/+ + clonazepam: t 16 = 5.355, ***P < 0.0001; Arid1b +/− + saline: t 16 = 5.170, ***P = 0.0001; Arid1b +/− + clonazepam: t 16 = 5.124, ***P = 0.0001; n = 9 male mice for saline-treated Arid1b +/+ , 9 male mice for clonazepam-treated Arid1b +/+ , 7 male mice for saline-treated Arid1b +/− , and 9 male mice for clonazepam-treated Arid1b +/− ; two-tailed Student's t test). c, Representative tracing of mouse movement in the open field test. d, Quantification of c (time in center: F 3,28 = 8.89, ***P < 0.0001 for Arid1b +/+ + saline vs. Arid1b +/− + saline; # P < 0.05 for Arid1b +/− + saline vs. Arid1b +/− + clonazepam; center entries: F 3,28 = 7.668, ***P < 0.0001 for Arid1b +/+ + saline vs. Arid1b +/− + saline; # P < 0.05 for Arid1b +/− + saline vs. Arid1b +/− + clonazepam; n = 9 mice (6 males, 3 females) for saline-treated Arid1b +/+ , 8 mice (5 males, 3 females) for clonazepam-treated Arid1b +/+ ; 9 mice (6 males, 3 females) for saline-treated Arid1b +/− , and 6 mice (5 males, 1 female) for clonazepamtreated Arid1b +/− ; one-way ANOVA with Bonferroni correction). e,f, Immobility time was measured in Arid1b +/+ and Arid1b +/− mice by (e) the forced swim test or (f) the tail suspension test (forced swim test: F 3,20 = 5.605, *P < 0.05 for Arid1b +/+ + saline vs. Arid1b +/− + saline; tail suspension test: F 3,20 = 14.8, ***P < 0.0001 for Arid1b +/+ + saline vs. Arid1b +/− + saline; *P < 0.05 for Arid1b +/+ + saline vs. Arid1b +/− + clonazepam; n = 6 mice (3 males, 3 females) for saline-treated Arid1b +/+ , 6 mice (4 males, 2 females) for clonazepam-treated Arid1b +/+ , 6 mice (3 males, 3 females) for saline-treated Arid1b +/− , and 6 mice (5 males, 1 female) for clonazepam-treated Arid1b +/− ; one-way ANOVA with Bonferroni correction). Data shown are mean ± s.e.m.
in the condensed chromatin could be transformed into a more relaxed structure, creating favorable environments for greater levels of gene transcription. The association of ARID1B with HATs or HDACs has been shown to regulate HAT and HDAC activity in mouse osteoblast cells 32 . However, we found no changes in activity of HATs or HDACs and no changes in the mRNA levels of multiple HAT, HDAC, and histone genes in Arid1b +/− cortices. These results suggest that ARID1B has no direct regulatory activity on HATs or HDACs in the brain. Rather, ARID1B may regulate histone modification via protein-protein interaction with histone modifiers. Recently, studies have shown that mutations in the gene encoding BRG1, the central subunit of the BAF chromatin-remodeling complex, reduce the binding of the BAF complex to acetylated histones 33, 34 . The BAF complex is required for histone acetylation by acetyltransferase proteins 34 . Our data showed that Arid1b haploinsufficiency decreases the expression levels of interneuronassociated genes Pvalb and Ntrk2 and alters epigenetic signatures in the brain. Still, understanding the genomic mechanisms and parvalbumin-neuron specificity of these mechanisms requires further work. It is possible that the decreased number of parvalbumin + neurons in Arid1b mutants could lead to reduced epigenetic signatures for phospho-CTD (Ser5) and H3K9ac at the Pvalb promoter. Alternatively, given the high-level changes in overall histone modifications in Arid1b mutant brains, the epigenetic changes may occur broadly in several other cell types.
Our mouse model effectively mirrors the behavioral characteristics of intellectual disability and ASD. Arid1b +/− and Arid1bconditional-knockout mice displayed impaired spatial learning, recognition memory, and reference memory. Open field and social behavior tests also revealed decreased social interaction in the mice. Mice with mutations in genes encoding Smarca2 and Actl6b, other subunits of the BAF complex, have severe defects in social interaction and long-term memory 35 . Thus, this chromatin remodeling complex may provide a cellular and molecular platform for normal intellectual and social behavior. In addition, Arid1b +/− mice showed heightened levels of anxiety-and depression-related behaviors, which are common symptoms of ASD 36 . For people with intellectual disability, the prevalence of anxiety disorders has likewise been shown to be much higher 37 . This may be due to reduced cognitive function and increased vulnerability to environmental demands. Communication difficulties may also make it more difficult for people with cognitive disabilities to deal with anxiety or fear. ARID1B haploinsufficiency may be responsible for multiple facets of characteristic ASD behaviors. Other isoforms of Arid1b that are not affected by the Arid1b mutation could exist in the mouse line. Additionally, it is possible that the genetic background for the mouse line may impact the effect of Arid1b haploinsufficiency. Thus it is important to consider allele specificity, genetic backgrounds, and knockout strategies for comparing phenotypes of other Arid1bhaploinsufficiency models. In a recent study, an Arid1b mouse generated using CRISPR-Cas9 gene editing shows impairments in social and anxiety behavior as well as body growth 38 . These phenotypes are consistent with our mouse model. However, that Arid1b mouse shows no learning, memory, or cognitive deficiencies, which contrasts with our findings and is unexpected given the association of Arid1b haploinsufficiency with intellectual disability.
GABA allosteric modulators, including clonazepam, a benzodiazepine, have been used to treat seizures and anxiety 39 . We found that clonazepam injection rescued deficits in object and social recognition and anxiety in Arid1b +/− mice. These results suggest that treatment with a benzodiazepine could be a potential pharmacological intervention for symptoms of ASD. Furthermore, our results suggest that pharmacological manipulation of GABA signaling is a potential treatment strategy for cognitive and social dysfunctions in ASD-or intellectual disability-associated disorders due to mutations in chromatin remodeling genes.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-017-0013-0.
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Nature NeuroscieNce held at a holding potential of -70 mV for mEPSCs and 0 mV for mIPSCs. For recording mEPSCs, 1 μ M tetrodotoxin and 100 μ M picrotoxin were added to the external recording solution; for mIPSCs, 1 μ M tetrodotoxin, 10 μ M NBQX, and 50 μ M d-AP5 were added. The slices were treated with 10 μ M clonazepam for 7 min after a 5-min baseline recording, followed by a 7-min wash. The signal was filtered at 2 kHz and digitized at 20 kHz using an Axon Digidata 1440 A analogto-digital board (Molecular Devices). Recordings were performed from three mice for each genotype. Recordings with a pipette with access resistance < 20 MΩ and < 20% changes during the duration of recording were included. mEPSC and mIPSC recordings were analyzed using Mini Analysis software (Synaposoft) with an amplitude threshold set at 6-8 pA for cultured neuron recordings and 5 pA for slice recordings. The frequency, amplitude, and decay were measured in each group.
Chromatin immunoprecipitation (ChIP) PCR assay. ChIP analysis was performed using the Magna ChIP Kit (Millipore). Briefly, Arid1b-mutant cortical tissues were cross-linked with 1.5% formaldehyde for 20 min at room temperature (20-25 °C) . This reaction was stopped by adding 0.125 M glycine for 5 min, and the samples were then washed three times with PBS at room temperature. Tissues were dissociated with 20-25 strokes by a Dounce homogenizer (Wheaton). Dissociated cells were then lysed and sonicated with a S220 High Performance Ultrasonicator (Covaris). Sonicated chromatin, Dynabeads protein A/G (Invitrogen), and appropriate antibodies were mixed and incubated overnight at 4 °C with gentle shaking. ChIP-grade anti-H3K9ac (Abcam, ab4441, 1:100), anti-ARID1B (Abcam, ab57461, 1:100), and anti-RNA polymerase II phospho-Ser5 (Abcam, ab5131, 1:100) were used. Beads were washed and reverse cross-linked according to the Magna ChIP Kit protocol. DNA captured by the immunoprecipitated protein was subjected to PCR.
BioID pull-down. Histone H3 (H3) cDNA was amplified by PCR and inserted into the MCS-BioID2-HA vector (Addgene) using EcoRI and BamHI sites. Proximity-dependent biotin identification (BioID) pull-down was performed as described previously 16 . The cloned H3 in MCS-BioID2-HA vector was transfected into MGE cells using Lipofectamine LTX (Life Technology), as recommended by the manufacturer. At 6 d in vitro (DIV), MGE cells were incubated with 50 μ M biotin for 18 h. After two PBS washes, cells were lysed in lysis buffer containing 50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 1 mM dithiothreitol, and 1× protease inhibitor (Thermo Fisher Scientific). Cells were collected and treated with Triton X-100 to a 2% final concentration. After two 1-min rounds of sonication each at 30% duty cycle and an output level of 4 (Sonifier-250; Branson), an equal volume of 50 mM Tris, pH 7.4, was added and the sample was cleaned using centrifugation at 16,500 g for 10 min. The supernatant was collected in a 15-mL conical tube and incubated with 300 μ L Dynabeads overnight. Beads were collected using a magnetic stand and washed twice with 2% (wt/vol) SDS; once with wash buffer containing 0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, and 50 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid, pH 7.5; once with wash buffer containing 250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA, and 10 mM Tris, pH 8; and once with 50 mM Tris.
Behavioral assays. All behavioral assays were done during the light cycle. Health conditions including weight, activity, and feeding were checked before assays. We used 3-to 4-month-old male and female mice for most behavioral assays. For social behavior assays, we used only male mice because sexual interactions between males and females may interfere with accurate interpretation of social behavior. All behavioral assays were done blind to genotypes, with age-matched littermates of mice.
Morris water maze test. Mice were introduced into the perimeter of a circular water-filled tank 110 cm in diameter and 91 cm in height (San Diego Instruments) with visual cues that were present on the tank walls as spatial references. The tank was divided into four equal quadrants (Q1-Q4) by lines drawn on the floor. A 10-cm circular Plexiglass platform was submerged 1 cm deep in Q2, hidden from the mice. The mice started the task from one of three quadrants (Q1, Q3 or Q4), varied by day of testing. Four trials were performed per mouse per day for 10 d. Each trial lasted 1 min and ended when the mouse climbed onto and remained on the hidden platform for 10 s. The mouse was given 20 s to rest on the platform between trials. The time taken by the mouse to reach the platform was recorded as its latency. The times for four trials was averaged and recorded as a result for each mouse. On day 11, the mice were subjected to a single 60-s probe trial without a platform to test memory retention. The mice started the trial from Q4, the number of annulus crossings was counted, and the swimming path was recorded and analyzed using the Ethovision XT 7 tracking software (Noldus).
T-maze test. Mice were first food-deprived to 85% of their free-feeding body weight before starting the appetitively motivated T-maze test. The T-maze apparatus contained a start arm (28 cm wide × 5 cm long × 10 cm high) and two identical goal arms (35 × 5 × 10 cm) surrounded by a 10-cm high wall. The test mouse was habituated to the T-maze apparatus and allowed to obtain food from the end of goal arms for 5 min. Ten training trials per day were then performed for 5 d. One reinforcer (Noyes sucrose pellet, 20 mg) was available in the designated goal arm for each trial. At the beginning of each test session, the mouse was placed in the start box at the bottom of the start arm. When the start box door was opened, the mouse was given a choice between entering either goal arm. If the mouse made the correct choice, it was given time to consume the sugar pellet, and then guided back into the start box for the next trial. Incorrect choices were not rewarded. For each successive trial, the reward was always placed in the same arm.
Novel-object recognition test. A test mouse was first habituated to an open field arena (35 × 42 cm) for 5 min. Following habituation, the test mouse was removed from the arena and two identical objects with size (10.5 × 4.5 × 2.5 cm) were placed in the opposite corners of the arena, 7 cm from the side walls. Then the test mouse was reintroduced into the center of the arena and allowed to explore the arena including the two novel objects for 10 min. After 6 h, one object was replaced with another novel object, which was of similar size but different shape and color than the previous object. The same test mouse was placed in the arena to explore the arena and the two objects. The movement of the mouse was recorded by a camera for 10 min and further analyzed by EthoVision XT 7 video tracking software (Noldus).
Rotarod test. Using an accelerating Rotamex 4/8 (Columbus Instruments
International) the rotarod test was performed by placing mice on rotating drums (3 cm in diameter) and measuring retention time on the rod. The speed of the rotarod accelerated from 4 to 40 rpm over a 5-min period. Three trials per day over a 16-d period were conducted. At least 20 min recovery time was allowed between trials.
Three-chamber test for social interaction and novelty behavior. Social behavior was evaluated as described previously 40 . A rectangular, transparent Plexiglas box divided by walls into three equal-sized compartments (Ugobasile) was used. Rectangular holes in the Plexiglas walls provide access between the chambers. For sociability testing, the test mouse was moved to the center chamber (chamber 2) with the entrances to the two connecting chambers blocked. A stimulus mouse (unfamiliar mouse) designated as 'stranger I' was placed in a wire enclosure in chamber 1. Then the openings to the flanking two chambers (1 and 3) were opened and the test mouse was allowed to explore the entire apparatus for 10 min. For the social novelty test, the stranger I mouse was randomly placed in one of the enclosures, while the test mouse had the choice of whether to investigate the stranger I mouse or a new novel mouse, designated 'stranger II' . This second novel mouse was taken from a different home cage and placed into the remaining empty wire enclosure. Time spent sniffing each partner by the test mouse was recorded for 10 min in both sociability and social novelty behavior tests. All apparatus chambers were cleaned with water and dried with paper towels between trials. At the end of each test day, the apparatus was sprayed with 70% ethanol and wiped clean with paper towels.
Open field social interaction test. Two Arid1b-mutant or wild-type mice were placed in opposite corners of the open field arena and allowed to explore freely for 10 min. Frequency and total duration of the active sociopositive behaviors including general sniffing, anogenital sniffing, following, mounting, and fighting were scored.
Spontaneous self-grooming. A mouse was placed in a clear plastic cage (17 × 32 × 14 cm). The mouse was allowed to freely explore the cage for the entirety of the test. The first 10 min served as a habituation period. The movement of the mouse was recorded by a camera for 30 min. Recorded grooming behaviors included head washing, body grooming, genital/tail grooming, and paw and leg licking.
Elevated plus maze test. The elevated plus maze test was performed as previously described 40 Forced swimming test. A mouse was placed individually into a glass cylinder (20 cm height, 17 cm diameter) filled with water to a depth of 10 cm at 25 °C. After 5 min, the animals were removed from the water, dried, and returned to their home cages. They were again placed in the cylinder 24 h later, and after the initial 1 min acclimatization period, the total duration of immobility was measured for 5 min. Motionless floating was considered immobile behavior. Corresponding author(s): Woo-Yang Kim
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Experimental design 1. Sample size
Describe how sample size was determined. The justification of sample size determination was described in the Method section of the manuscript. To determine and confirm sample sizes (N), we performed a power analysis. The values for the power (1-beta) and the type I error rate (alpha) were 0.8 and 0.05 (or 0.01), respectively. We described this in the Method section of the manuscript.
Data exclusions
Describe any data exclusions. Exclusion criteria for mice were based on abnormal health conditions including weights below 15g at 6 weeks and noticeably reduced activity or feeding as used in previous studies ( (2002)). We described this in the Method section of the manuscript.
Replication
Describe whether the experimental findings were reliably reproduced.
We repeated each experiment more than three times and reproduced the results. We utilized more than three sets of cultures or tissues from more than three animals for each experiment. We described animal numbers and statistics in the legend section of the manuscript. We also performed each experiment using different methodologies to confirm the results.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Each experiment in this study was performed randomized. Animals were assigned randomly to the various experimental groups, and data were collected and processed randomly. The allocation, treatment, and handling of animals were the same across study groups. We described randomization in the Method section of the manuscript.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Each experiment in this study was performed blind. The individuals conducting the experiments were blinded to group allocation and the allocation sequence. We described blinding in the Method section of the manuscript.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Data were analyzed using the GraphPad Prism and presented as means ± SEM. Normal distribution was tested using the Kolmogorov-Smirnov test and variance was compared. Unless otherwise stated, statistical significance was determined using two-tailed unpaired Student's t-tests for two population comparison or oneway ANOVA followed by the Bonferroni's post hoc test for multiple comparisons. We described this in the Method section of the manuscript.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There is no restriction on availability of materials.
